Business Wire

Fresenius Kabi Introduces Bortezomib for Injection

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today the availability in the United States of Bortezomib for Injection. Fresenius Kabi Bortezomib for Injection is available as a single ...
FiercePharma

FDA Approves VELCADE® (bortezomib) for Injection for Previously Untreated Patients with Mantle Cell Lymphoma

This approval extends the benefit of VELCADE for mantle cell lymphoma (MCL) to previously untreated patients in addition to relapsed or refractory patients First treatment approved by the U.S. Food ...
FierceBiotech

FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma

CAMBRIDGE, Mass. and OSAKA, Japan, June 20 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) today announced that ...
FierceBiotech

Takeda to Co-Promote VELCADE® (bortezomib) for Injection in Japan

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (“Takeda,” TSE:4502) and its wholly owned subsidiary Millennium: The Takeda Oncology Company (“Millennium”) ...
Nasdaq

Dr. Reddy's Laboratories Announces the Launch of Bortezomib for Injection 3.5 mg/vial for Intravenous Use Only in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...
EurekAlert!

VELCADE® for injection receives EU marketing authorisation for second-line use in multiple myeloma

HIGH WYCOMBE, UK, 28th April 2005 – Ortho Biotech, the biopharmaceutical division of Janssen-Cilag, today announced that the European Commission has approved the use of VELCADE® (bortezomib) for ...
FiercePharma

Millennium Provides Update on sNDA for VELCADE in Relapsed Follicular Lymphoma

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced that it is withdrawing the ...
Seeking Alpha

Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and Shilpa Medicare ...
Reuters

Millennium Pharm Velcade for injection based therapies Produced Complete Remission Rates as High as 54%

Co reported on the presentation of results from clinical trials of Velcade based therapies that showed high complete remission / complete response rates in previously treated multiple myeloma patients ...
Business Wire

Dr. Reddy's Laboratories Announces the Launch of Bortezomib for Injection 3.5 mg/vial for Intravenous Use Only in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...
The Financial

Takeda to Co-promote VELCADE (bortezomib) for Injection in Japan

The FINANCIAL — Takeda Pharmaceutical Company Limited (“Takeda,” TSE:4502) and its wholly owned subsidiary Millennium: The Takeda Oncology Company (“Millennium”) on May 10 announced that Takeda has ...